SMT201600194B - Composizione e formulazione comprendente iduronato-2-s0lfatasi umano ricombinante e suo metodo di preparazione - Google Patents

Composizione e formulazione comprendente iduronato-2-s0lfatasi umano ricombinante e suo metodo di preparazione

Info

Publication number
SMT201600194B
SMT201600194B SM201600194T SM201600194T SMT201600194B SM T201600194 B SMT201600194 B SM T201600194B SM 201600194 T SM201600194 T SM 201600194T SM 201600194 T SM201600194 T SM 201600194T SM T201600194 B SMT201600194 B SM T201600194B
Authority
SM
San Marino
Prior art keywords
recombinant
preparation
composition
human
formulation including
Prior art date
Application number
SM201600194T
Other languages
English (en)
Inventor
Thong-Gyu Jin
Yo Kyung Chung
Sang Hoon Paik
Yoo Chang Park
Jinwook Seo
Yong Woon Choi
Jong Mun Son
Yong-Chul Kim
Original Assignee
Green Cross Corp
Medigenebio Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46716009&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SMT201600194(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Green Cross Corp, Medigenebio Corp filed Critical Green Cross Corp
Publication of SMT201600194B publication Critical patent/SMT201600194B/it

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/16Hydrolases (3) acting on ester bonds (3.1)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/465Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/04Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y301/00Hydrolases acting on ester bonds (3.1)
    • C12Y301/06Sulfuric ester hydrolases (3.1.6)
    • C12Y301/06013Iduronate-2-sulfatase (3.1.6.13)
SM201600194T 2011-06-24 2016-06-22 Composizione e formulazione comprendente iduronato-2-s0lfatasi umano ricombinante e suo metodo di preparazione SMT201600194B (it)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161500994P 2011-06-24 2011-06-24
KR1020120012718A KR101158673B1 (ko) 2011-06-24 2012-02-08 재조합 인간 이듀로네이트-2-설파타아제를 포함하는 조성물, 제제 및 이의 제조방법
PCT/KR2012/004734 WO2012177020A2 (en) 2011-06-24 2012-06-15 Composition and formulation comprising recombinant human iduronate-2-sulfatase and preparation method thereof

Publications (1)

Publication Number Publication Date
SMT201600194B true SMT201600194B (it) 2016-08-31

Family

ID=46716009

Family Applications (1)

Application Number Title Priority Date Filing Date
SM201600194T SMT201600194B (it) 2011-06-24 2016-06-22 Composizione e formulazione comprendente iduronato-2-s0lfatasi umano ricombinante e suo metodo di preparazione

Country Status (28)

Country Link
US (2) US9206402B2 (it)
EP (1) EP2723369B2 (it)
JP (2) JP5844459B2 (it)
KR (2) KR101158673B1 (it)
CN (1) CN103635203B (it)
AU (2) AU2012274215B2 (it)
BR (1) BR112013032193A2 (it)
CA (1) CA2839674C (it)
CO (1) CO6862105A2 (it)
CY (1) CY1117861T1 (it)
DK (1) DK2723369T4 (it)
EA (1) EA026499B1 (it)
ES (1) ES2575377T5 (it)
FI (1) FI2723369T4 (it)
HK (1) HK1195731A1 (it)
HR (1) HRP20160490T4 (it)
HU (1) HUE027431T2 (it)
IL (1) IL230120B (it)
MX (1) MX341946B (it)
MY (1) MY166647A (it)
PE (1) PE20140734A1 (it)
PL (1) PL2723369T5 (it)
PT (1) PT2723369E (it)
RS (1) RS54822B2 (it)
SI (1) SI2723369T2 (it)
SM (1) SMT201600194B (it)
UA (1) UA109949C2 (it)
WO (1) WO2012177020A2 (it)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012101671A1 (en) * 2011-01-25 2012-08-02 Jcr Pharmaceuticals Co., Ltd. Method for production of human recombinant iduronate 2-sulfatase
US20160145589A1 (en) 2011-06-24 2016-05-26 Green Cross Corporation Composition and formulation comprising recombinant human iduronate-2-sulfatase and preparation method thereof
KR101158673B1 (ko) * 2011-06-24 2012-07-03 주식회사 지씨바이오 재조합 인간 이듀로네이트-2-설파타아제를 포함하는 조성물, 제제 및 이의 제조방법
KR101380740B1 (ko) 2012-06-29 2014-04-11 쉐어 휴먼 제네텍 세러피스, 인코포레이티드 이듀로네이트-2-설파타제의 정제
US20140004097A1 (en) * 2012-06-29 2014-01-02 Shire Human Genetic Therapies, Inc. Method of producing recombinant iduronate-2-sulfatase
US9150841B2 (en) 2012-06-29 2015-10-06 Shire Human Genetic Therapies, Inc. Cells for producing recombinant iduronate-2-sulfatase
CN106153745B (zh) * 2015-03-31 2020-11-10 三生国健药业(上海)股份有限公司 抗体蛋白二硫键配对分析方法
CN106153746B (zh) * 2015-03-31 2020-11-06 三生国健药业(上海)股份有限公司 IgG2型单抗二硫键配对分析方法
CN106153744B (zh) * 2015-03-31 2020-11-10 三生国健药业(上海)股份有限公司 融合蛋白二硫键配对分析方法
KR20170004814A (ko) * 2015-07-02 2017-01-11 주식회사 녹십자 헌터증후군 치료제
WO2017003270A1 (ko) * 2015-07-02 2017-01-05 주식회사 녹십자 헌터증후군 치료제 및 치료방법
SG11201805598WA (en) * 2015-12-30 2018-07-30 Green Cross Corp Methods and compositions for treating hunter syndrome
US20190055513A1 (en) * 2016-02-22 2019-02-21 Agency For Science, Technology And Research Cell culture medium
KR20190139951A (ko) 2017-04-14 2019-12-18 리젠엑스바이오 인크. 인간 뉴런 또는 신경교 세포에 의해 생성된 재조합 인간 이두로네이트-2 설파타제(ids)를 이용한 뮤코다당증 ii형의 치료
WO2019022563A2 (ko) * 2017-07-28 2019-01-31 한미약품 주식회사 이두로네이트 2-설파타제 결합체
MA50746A (fr) 2017-10-02 2020-08-12 Denali Therapeutics Inc Protéines de fusion comprenant des enzymes d'enzymothérapie substitutive
KR20190136271A (ko) 2018-05-30 2019-12-10 주식회사 녹십자 대뇌 측뇌실 투여에 의해 헌터증후군을 치료하기 위한 방법 및 조성물
EP3846780A4 (en) * 2018-09-05 2022-11-30 Sangamo Therapeutics, Inc. ENZYMATIC TESTS FOR QUANTIFICATION OF THERAPY IN PATIENTS WITH MUCOPOLYSACCHARIDOSE TYPE I OR II
EP3826664A4 (en) 2019-02-06 2022-10-26 Sangamo Therapeutics, Inc. METHOD FOR THE TREATMENT OF TYPE I MUCOPOLYSACCHARIDOSES

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5932211A (en) 1991-11-12 1999-08-03 Women's And Children's Hospital Glycosylation variants of iduronate 2-sulfatase
IL155588A0 (en) 2003-04-27 2003-11-23 Metabogal Ltd Methods for expression of enzymatically active recombinant lysosomal enzymes in transgenic plant root cells and vectors used thereby
AU2004210936C1 (en) 2003-02-11 2010-12-02 Takeda Pharmaceutical Company Limited Diagnosis and treatment of Multiple Sulfatase Deficiency and other using a Formylglycine Generating Enzyme (FGE)
WO2005113765A2 (en) * 2004-05-06 2005-12-01 Biomarin Pharmaceutical Inc. Methods of activation of sulfatases and methods and compositions of using the same
KR101158673B1 (ko) * 2011-06-24 2012-07-03 주식회사 지씨바이오 재조합 인간 이듀로네이트-2-설파타아제를 포함하는 조성물, 제제 및 이의 제조방법
KR101380740B1 (ko) 2012-06-29 2014-04-11 쉐어 휴먼 제네텍 세러피스, 인코포레이티드 이듀로네이트-2-설파타제의 정제

Also Published As

Publication number Publication date
EA026499B1 (ru) 2017-04-28
EA201490149A1 (ru) 2014-09-30
CY1117861T1 (el) 2017-05-17
JP2016056179A (ja) 2016-04-21
AU2016201487B2 (en) 2017-10-19
KR101158673B1 (ko) 2012-07-03
EP2723369A4 (en) 2014-12-24
EP2723369B2 (en) 2023-05-10
UA109949C2 (uk) 2015-10-26
MY166647A (en) 2018-07-18
CA2839674C (en) 2018-04-24
ES2575377T5 (es) 2023-10-26
US20150320843A1 (en) 2015-11-12
WO2012177020A2 (en) 2012-12-27
AU2016201487A1 (en) 2016-03-24
PL2723369T3 (pl) 2016-09-30
RS54822B2 (sr) 2023-09-29
PT2723369E (pt) 2016-06-03
MX341946B (es) 2016-09-08
CN103635203A (zh) 2014-03-12
RS54822B1 (sr) 2016-10-31
WO2012177020A3 (en) 2013-04-04
SI2723369T1 (sl) 2016-09-30
AU2012274215A1 (en) 2014-02-20
CN103635203B (zh) 2016-06-08
BR112013032193A2 (pt) 2017-11-21
EP2723369A2 (en) 2014-04-30
PE20140734A1 (es) 2014-07-04
JP6000432B2 (ja) 2016-09-28
KR20160030591A (ko) 2016-03-21
HUE027431T2 (en) 2016-09-28
US20140242059A1 (en) 2014-08-28
AU2012274215B2 (en) 2015-12-10
DK2723369T3 (en) 2016-06-13
US9206402B2 (en) 2015-12-08
US9249397B2 (en) 2016-02-02
MX2013015127A (es) 2014-06-11
HK1195731A1 (zh) 2014-11-21
CA2839674A1 (en) 2012-12-27
FI2723369T4 (fi) 2023-08-31
DK2723369T4 (da) 2023-07-24
KR101910124B1 (ko) 2018-10-19
HRP20160490T1 (hr) 2016-08-12
IL230120B (en) 2020-09-30
WO2012177020A9 (en) 2013-02-14
PL2723369T5 (pl) 2024-02-05
ES2575377T3 (es) 2016-06-28
NZ620284A (en) 2015-11-27
JP2014520143A (ja) 2014-08-21
HRP20160490T4 (hr) 2023-09-15
CO6862105A2 (es) 2014-02-10
EP2723369B1 (en) 2016-04-13
JP5844459B2 (ja) 2016-01-20
SI2723369T2 (sl) 2023-08-31

Similar Documents

Publication Publication Date Title
SMT201600194B (it) Composizione e formulazione comprendente iduronato-2-s0lfatasi umano ricombinante e suo metodo di preparazione
HRP20181448T1 (hr) Antihelmintski spojevi i sastavi te postupak za njihovu uporabu
BR112013013025A2 (pt) composições i-i e produtos e usos desta
EP2611413A4 (en) SKIN COMPOSITIONS AND THEIR APPLICATIONS
SG10202009963PA (en) Melanin modification compositions and methods of use
FI20135146L (fi) Farmaseuttiset koostumukset ja hoitomenetelmät
BR112012022878A2 (pt) composto, composição farmacêutica, uso do compostos e método de tratamento
BR112014006291A2 (pt) composição e utilização da composição
ZA201402820B (en) Pharmaceutical compositions comprising dgla and/or 15-hetre and methods of use thereof
EP2709642A4 (en) THERAPEUTIC COMPOSITIONS OF CERTAIN HERBAL FORMULATIONS AND USES THEREOF
EP2753337A4 (en) COMPOSITIONS COMPRISING BETA-GLUCANS AND METHODS OF USE
EP2755668A4 (en) COMPOSITIONS OF HYR1 AND TREATMENT PROCEDURES THEREWITH
IL231505A0 (en) Pharmaceutical preparation and method for its production
BR112013034066A2 (pt) método de administração e tratamento
BR112013033472A2 (pt) derivado de camptotecina e método de preparação do mesmo e composição farmacêutica e aplicação
BR112013022530A2 (pt) método terapêutico homeopático e composições
EP2575891A4 (en) FORMULATIONS PRESERVING BIOACTIVITY AND METHODS FOR THEIR PREPARATION
GB201002278D0 (en) composition and method of preparation
TH119698B (th) องค์ประกอบแบบเสริมฤทธิ์และวิธีการใช้
PL398988A1 (pl) (Z)-6-O-ß-D-glukopiranozylo-4'-hydroksy-4-metoksy-7-prenyloauron i sposób jego wytwarzania
ITTO20110635A1 (it) Composizione farmaceutica di combinazione e metodi per trattare e prevenire le malattie infettive
IL221337A0 (en) Vaccine compositions and methods of use thereof
TH123117B (th) องค์ประกอบรวมทางเภสัชกรรมที่คงสภาพ